24/7 Market News Snapshot 10 March, 2025 – CervoMed Inc. Common Stock (NASDAQ:CRVO)

March 10, 2025

DENVER, Colo., 10 March, 2025 (247marketnews.com) – (NASDAQ:CRVO) are discussed in this article.
CervoMed Inc. has reported a notable decline in its stock price, opening at $2.18 before falling to $2.071, marking a decrease of approximately 6.29%. The trading volume has reached 630.82K shares, suggesting increased market activity that may indicate selling pressure. This bearish trend reflects a potential resistance level at $2.18, with investors monitoring support levels around $2.00 as they assess future price movements. If the selling persists, CervoMed may test lower support levels, while gains above $2.18 could signal a reversal in fortunes. The technical outlook remains cautious in the near term amid current market dynamics.

In more positive news, CervoMed has also revealed encouraging results from the extension phase of its Phase 2b RewinD-LB study, which is investigating neflamapimod for the treatment of dementia with Lewy bodies (DLB). Initial findings from the first 16 weeks of this phase indicate significant improvements in both plasma drug concentrations and clinical outcomes. The trial demonstrated a statistically significant reduction in the Clinical Dementia Rating Sum of Boxes (CDR-SB), outperforming both the earlier capsule formulation and the placebo group (p<0.001). Additional results supported by a positive Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) assessment (p=0.035) reinforce the potential efficacy of neflamapimod. Dr. James E. Galvin, a Co-Principal Investigator of the study, emphasized the impactful nature of these findings for DLB patients and their families, spotlighting the pressing need for effective treatments in a space currently devoid of approved therapies. CEO John Alam expressed enthusiasm over the study's outcomes and their implications for advancing to Phase 3 clinical trials. Furthermore, the trial noted a reduction in falls among participants, suggesting an enhanced safety profile for the investigational drug. CervoMed is poised to engage with regulatory authorities to expedite the developmental trajectory of neflamapimod, addressing the significant unmet needs faced by DLB patients.

Related news for (CRVO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.